The University of Barcelona and Cancer Research Technology Partner for AT514 Drug Development Collaboration

London, UK and Barcelona, Spain, 7 February 2006 – Cancer Research Technology Limited (CRT, the specialist oncology development and commercialisation company) and The University of Barcelona have initiated a collaboration to develop AT514 (serratamolide) and analogues for the treatment of cancer. AT514 is a microbial depsipeptide, identified as an anti-cancer agent by scientists at the University of Barcelona.

The University of Barcelona will conduct development studies in collaboration with CRT and have assigned the rights to the use of AT514 in the treatment of cancer to CRT. Commercialisation of AT514 will be led by CRT and both parties will share future revenues.

This is the first collaboration between CRT and The University of Barcelona. It is hoped that this partnership will result in the generation of an important new cancer therapy and lead to further joint oncology drug development and commercialisation projects.

ENDS

For further information:

Notes for editors:

Cancer Research Technology Limited

Cancer Research Technology Limited (CRT) is a specialist technology development and commercialisation company which aims to develop new discoveries in cancer research for the benefit of cancer patients. CRT is wholly owned by Cancer Research UK, the largest independent funder of cancer research in the world. CRT works closely with leading international cancer scientists and their institutes to protect intellectual property arising from their research and to establish links with commercial partners. CRT facilitates the discovery, development and marketing of new cancer therapeutics, vaccines, diagnostics and enabling technologies. Further information about CRT can be found at www.cancertechnology.com.

The University of Barcelona

The Universitat de Barcelona (UB) is the number one university research centre in Spain and one of the leading centres in Europe, in terms of both the number of research programmes and for the level of excellence achieved in this field. More than 4,500 academics work in the 100 departments, the majority of which are linked to the 600 consolidated research groups. The commitment of UB to research training is illustrated by the award of more than 450 doctorates each year. UB is the top Spanish university in many fields of knowledge and it is also the leader in scientific productivity.

In recent years, the tradition, dynamism and interdisciplinary nature of UB’s centres has enabled it to undertake an active policy of approaching companies and public services. This has resulted in a spectacular increase in the transfer of knowledge and results between UB research groups and commercial parties and also to the generation of technological springboards, companies and other initiatives through the Fundació Bosch i Gimpera and Scientific Park of Barcelona.

Return to top of page